| 2025-11-10 |
详情>>
股本变动：
变动后总股本1581.71万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-3.03美元,归母净利润-2821.2万美元,同比去年增长5.46%
|
| 2025-08-08 |
详情>>
内部人交易：
GILEAD SCIENCES, INC.股份增加2295920.00股
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-2.51美元,归母净利润-1901.6万美元,同比去年增长6.00%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-1.17美元,归母净利润-881.8万美元,同比去年增长2.85%
|
| 2025-04-23 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Elect the ten nominees named in the attached proxy statement to our Board of Directors (the Board);
2.Approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.Approve an amendment to the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan (the 2018 Plan) to increase the number of shares reserved for issuance thereunder by 375,000 shares;
5.Approve an additional amendment to the 2018 Plan to increase the number of shares reserved for issuance thereunder by 225,000 shares solely to support a broad-based supplemental retention grant program;
6.Approve an amendment to the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan to increase the number of shares reserved for issuance thereunder to 225,000 shares;
7.Vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-6.69美元,归母净利润-4017.7万美元,同比去年增长34.38%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-5.12美元,归母净利润-2984.2万美元,同比去年增长40.63%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-3.64美元,归母净利润-2022.9万美元,同比去年增长43.57%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-1.66美元,归母净利润-907.7万美元,同比去年增长52.10%
|
| 2024-04-17 |
股东大会：
将于2024-05-29召开股东大会
会议内容 ▼▲
- 1.Elect the ten nominees named in the attached proxy statement to our Board of Directors (the Board);
2.Approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.Vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve our named executive officers’ compensation;
4.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
5.Approve the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 220,000 shares;
6.Approve the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan to increase the number of shares reserved for issuance thereunder to 164,500 shares and remove the maximum number of shares purchasable under the plan per offering period;
7.Vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-13.38美元,归母净利润-6122.8万美元,同比去年增长34.23%
|
| 2024-02-12 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2024-02-10 |
复牌提示：
2024-02-09 19:50:00 停牌，复牌日期 2024-02-12 09:00:00
|
| 2023-12-21 |
股东大会：
将于2024-01-31召开股东大会
会议内容 ▼▲
- 1.Approve a series of alternate amendments to our Sixth Amended and Restated Certificate of Incorporation to effect, at the discretion of our Board of Directors (the Board), a reverse stock split of our common stock at a ratio to be determined by the Board within a range of 1-for-7 to 1-for-17 (or any number in between) without reducing the authorized number of shares of the common stock (the Reverse Stock Split Proposal);
2.Approve, subject to certain conditions, the issuance of shares of common stock to Gilead Sciences, Inc. pursuant to Nasdaq Listing Rules 5635(a) and 5635(b) (the Nasdaq Proposal);
3.Approve an adjournment of the Special Meeting to a later date or dates, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals (the Adjournment Proposal).
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.97美元,归母净利润-5026.6万美元,同比去年增长28.90%
|
| 2023-08-09 |
详情>>
业绩披露：
2023年中报每股收益-0.69美元,归母净利润-3584.6万美元,同比去年增长24.62%
|
| 2023-04-12 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.Elect the eight nominees named in the attached proxy statement to our Board of Directors (the Board);
2.Approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.Approve an amendment to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 2,000,000 shares;
5.Amend and restate our Sixth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 150,000,000 to 225,000,000;
6.Vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2022-04-12 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees named in the attached proxy statement to our Board of Directors (the Board);
2.To approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To approve an amendment to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 2,000,000 shares;
5.To amend and restate our Fifth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000;
6.To approve a stock option exchange program for non-executive employees;
7.To vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-07 |
股东大会：
将于2021-05-20召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees named in the attached proxy statement to our Board of Directors (the Board);
2.To approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.To approve an amendment to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 2,000,000 shares;
5.To amend and restate the 2018 Employee Stock Purchase Plan to increase the number of shares reserved for issuance thereunder by 900,000 shares and increase the maximum number of shares purchasable under the plan to 2,500 per offering period;
6.To vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2020-05-07 |
财报披露：
美东时间 2020-05-07 盘后发布财报
|
| 2020-04-27 |
股东大会：
将于2020-06-11召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees named in the attached proxy statement to our Board of Directors (the Board);
2.To approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To approve an amendment to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares;
5.To approve an amendment and restatement of our Fourth Amended and Restated Certificate of Incorporation to enable stockholders who hold in the aggregate at least 25% of our outstanding common stock to request special stockholder meetings;
6.If properly presented at the Annual Meeting, to vote on a stockholder proposal requesting the Board to take steps necessary to give stockholders who hold at least 15% of our outstanding common stock the right to request a special stockholder meeting;
7.To vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2019-04-04 |
股东大会：
将于2019-05-17召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees named in the attached proxy statement to our Board of Directors;
2.To approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To approve an amendment to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan to, among other things, increase the number of shares reserved for issuance thereunder by 1,100,000 shares;
5.To vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2018-04-19 |
股东大会：
将于2018-05-30召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees named in the attached proxy statement to the Board of Directors;
2.To approve, on a non-binding advisory basis, our named executive officers’ compensation, as disclosed in the proxy statement accompanying this notice;
3.To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve our named executive officers’ compensation;
4.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
5.To amend and restate our Third Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000;
6.To approve the Assembly Biosciences, Inc. 2018 Stock Incentive Plan;
7.To approve the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan;
8.To vote on such other matters that may properly come before the meeting and any adjournment or postponement thereof.
|
| 2017-04-21 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1.To elect each of our seven nominees for the Board of Directors to serve until the 2018 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal;
2.To vote on a non-binding, advisory resolution approving the compensation of the Company’s named executive officers;
3.To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
4.To transact such other business as may properly come before the meeting and any adjournments or postponements thereof.
|
| 2016-04-22 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1.To elect each of our seven nominees for the Board of Directors to serve until the 2017 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal;
2.To approve the amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “Amended and Restated 2014 Stock Incentive Plan”), to among other things, (i) increase the aggregate number of shares of common stock authorized for issuance under the 2014 Stock Incentive Plan from 2,560,000 (post reverse stock split basis) to 4,160,000, (ii) impose minimum vesting requirements for awards granted to employees and directors, and (iii) change the name of the plan to reflect the name change of the Company;
3.To approve a non-binding advisory resolution approving the compensation of the Company’s named executive officers;
4.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.To transact such other business as may properly come before the meeting and any adjournments or postponements thereof.
|